Fibroblast Growth Factor 23 and α-Klotho Protein Are Associated with Adverse Clinical Outcomes in Non-Dialysis CKD Patients

Conclusions: In patients with CKD stages 1 –5, the combination of higher cFGF-23 and lower sKlotho levels along with mGFR and serum phosphate was associated with adverse clinical outcomes. The utility of combinations of traditional and novel biomarkers to predict outcomes warrants further study.Kidney Blood Press Res
Source: Kidney and Blood Pressure Research - Category: Urology & Nephrology Source Type: research